Longboard Pharmaceuticals (LBPH) announced that the U.S. Food and Drug Administration has granted orphan drug designation to bexicaserin in the treatment of Lennox-Gastaut Syndrome.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LBPH:
- Longboard Pharmaceuticals Inc options imply 0.8% move in share price post-earnings
- Largest borrow rate increases among liquid names
- Longboard Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright
- Longboard Pharmaceuticals downgraded to Neutral from Buy at B. Riley
- Lundbeck Acquires Longboard Pharmaceuticals for $2.6 Billion